Open Label, 12-Week Clinical Trial to Assess Efficacy, Safety, Treatment Adherence and Quality of Life Impact of Mometasone Furoate Dry Powder 400 Mcg Once-Daily in Persistent Mild-Moderate Asthmatic Patients at Least 12 Years Old.

Trial Profile

Open Label, 12-Week Clinical Trial to Assess Efficacy, Safety, Treatment Adherence and Quality of Life Impact of Mometasone Furoate Dry Powder 400 Mcg Once-Daily in Persistent Mild-Moderate Asthmatic Patients at Least 12 Years Old.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Mometasone (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms APEGO
  • Sponsors Schering-Plough
  • Most Recent Events

    • 19 Jul 2011 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
    • 21 Aug 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 21 Aug 2009 Planned end date changed from 1 Mar 2009 to 1 Jul 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top